Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. - Wikidata - wikimedia - TriplyDB

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

http://www.wikidata.org/entity/Q33803406

about

NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630 A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.Utilizing protein structure to identify non-random somatic mutations.Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk Similarity of markers identified from cancer gene expression studies: observations from GEO PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice The complexity of prostate cancer: genomic alterations and heterogeneity.Cell mates: paracrine and stromal targets for prostate cancer therapy.Circulating tumor cells: utopia or reality?Disruption of prostate epithelial differentiation pathways and prostate cancer development.The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma.High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.Analysis of origin and protein-protein interaction maps suggests distinct oncogenic role of nuclear EGFR during cancer evolution.NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.Coordinated targeting of the EGFR signaling axis by microRNA-27a*.FOXC1: an emerging marker and therapeutic target for cancer.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).Advances in prostate cancer research models: From transgenic mice to tumor xenografting models.Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors

P2860

Q27320669-C19F097E-B858-4D7D-9E13-5B48BCB83189 Q28082793-5F7E36B5-A54F-4200-8B5C-AAB619CD5514 Q28540120-1A6B0C22-825E-4D71-AB14-16CFC68D23C0 Q30360645-5B773D93-FFA2-493A-893C-7DA84AC66DAD Q30431811-3BFB9AD2-ADF4-4AB7-B95F-7396AFB60BC9 Q31049380-8296CE9C-8984-4F71-9679-D7D473222070 Q33814357-D54C1910-C753-43D7-A371-B2850282A9CD Q34543873-7941F0E2-894B-4C2A-828F-15E8C5C66519 Q34651354-DF823CCE-AE0C-40C7-BE31-64F64E1149C8 Q34654728-BC6D2AB4-D6E3-4A23-984F-5F2B717270E3 Q34736426-AF9EBB20-7F8C-40A5-AF2C-F142A0DFC6FF Q35764344-CD90DA9E-7E5C-4887-8FFB-06F0F7B8A5A9 Q35811012-97CC1802-FA43-47CE-BD6A-2B4895537B9B Q35838821-3EFCFC08-461E-494E-9B4B-5322A7E0CA4B Q36238822-74A2D331-A28E-4844-BCDE-3015FD10AA5F Q36543668-67FB5D28-93BB-4D3D-B2B1-62EDA5CE920A Q36758880-4B0C3CCC-A76E-43EF-AE1F-9CA2E600E4AA Q37615017-C37A9F6B-89C4-421D-9A72-575E879B6133 Q37699402-BE2C2F30-6D90-428B-B263-1C43173BA194 Q38058243-5BC4CA2F-F227-4826-9C67-FD408C82A34D Q38121792-FC35083F-3A41-4D21-A1D7-548CA191D594 Q38131799-2E4B6743-07EA-40EA-899A-012BE2A7D316 Q38160495-251CF2DD-CD49-4912-A493-787780E9566D Q38699560-976A9CC9-35D8-4150-BA90-785BEA8E9713 Q38750494-EF7DD234-2974-45F5-8A28-CD2C09C24B12 Q38851322-FD17627B-4D2E-4B79-815F-BE8ED7EE7F4D Q38940292-D0E1C9D8-BFBC-4075-BBC8-EA049BF58903 Q39107545-49BEE252-580C-49D3-916D-0B96E02283E9 Q39176111-D5CA3907-2DC3-42E9-8EDD-5DB603FB1C4F Q39257661-6737102B-97D8-4FC1-B963-1E4BB066BB61 Q40199561-4BC2E662-8E05-4F70-BAB1-6A35A4271ABE Q41839517-3F3F43F5-5BA1-416D-9F4D-1EA5A500C1E8 Q44208783-9466CD10-DC53-420F-AB4F-AEC8B0AE13F3 Q54279370-6D6BC7B0-E615-47AF-8641-47DE9F855864 Q54373177-DED5A74F-DCDF-4734-8AE5-15DC808472D4 Q55237889-D88EBDE2-3E73-452F-B15E-8AB45DD59261 Q59129702-A1A5069F-7C86-4330-B83E-D9890BFD8664

P2860

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

http://www.wikidata.org/entity/Q33803406

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@ast

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@en

type

label

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@ast

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@en

prefLabel

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@ast

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@en

P1433

Q33803406-A5573710-871D-4B0F-A55C-0A161BDFF435

P1476

Q33803406-4DBF42AC-41EB-4E85-BB50-18DAE07DB760

P2093

Q33803406-01A7A034-D17B-4362-ACE0-7DD049593166

Q33803406-0D34D20B-06BA-4828-88E5-A6C6E0995C1D

Q33803406-3A8BF033-37DC-443E-8D36-5F27A84BE9F4

Q33803406-3AE1663C-4F69-44AA-B1FF-CC3682A5F3E1

Q33803406-43246FF6-4462-42A7-A7F7-7B55E74A2BAA

Q33803406-5891589C-94F2-47D6-A55A-02BB23149A9C

Q33803406-9412A279-9CEE-4C74-B1BC-301BADE6F1AE

Q33803406-9F178559-B5E5-4432-A3EE-65E3A9EFDF4D

Q33803406-D1951445-C9E3-4329-AD6D-59FDB41B5403

Q33803406-DFC9D465-303A-4757-A79B-A728BF17183B

P2860

Q33803406-0E274AB3-E285-407E-8EA4-42E696822988

Q33803406-0F294B14-6BA6-40AE-9315-BDA05B554EE3

Q33803406-17959A06-E24D-45AC-982D-899735B94440

Q33803406-1DF78355-FDD6-4E7E-85EF-F31A72ACD767

Q33803406-2CDF1614-9B1E-4569-AEC5-7E790FC036B7

Q33803406-45AC00A3-4329-4D82-9749-E6D0BB91BF60

Q33803406-4876108E-A966-41F7-A0DD-46B9F1CFD0C0

Q33803406-4E2F9C86-1DAB-45B1-9AB5-C3E6DB1D9378

Q33803406-52921E85-4F09-4CC7-90B9-C134CF1D8F2C

Q33803406-5543CCDF-965D-40E7-9888-127624323834

P2888

Q33803406-E4A83FF3-5F97-4978-904E-DCC0923CD603

P304

Q33803406-D7DFED26-398C-4AEB-9BFF-332AEBC282AB

P31

Q33803406-101CC040-E776-4D53-A990-9B6E9D87FA29

P356

Q33803406-F4FCA577-D60B-4101-8CB4-29758412E655

P407

Q33803406-E67A8F45-EF75-436D-9439-DED3DA9CA063

P478

Q33803406-ACA73E04-F5C0-4F4A-8898-A164184492C7

P577

Q33803406-4F46E9D7-7CAD-4A41-AF53-31A95FEF34B8

P5875

Q33803406-72371839-AF7C-4A3C-B5C6-721ABA56D4E5

P6179

Q33803406-62089F68-FFF8-4241-A722-C0EE57AEF51F

P698

Q33803406-2B3AC9D0-69E9-424B-9059-89B5731C47D2

P932

Q33803406-9B25EE8A-BA26-46CF-8387-75C8F0139634

P356

1471-2407-11-31

P1433

P1476

Epidermal Growth Factor Recept ...... on in primary prostate cancer.

@en

P2093

Bruno Torchio

http://www.w3.org/2001/XMLSchema#string

Caterina Peraldo-Neia

http://www.w3.org/2001/XMLSchema#string

Filippo Montemurro

http://www.w3.org/2001/XMLSchema#string

Giorgia Migliardi

http://www.w3.org/2001/XMLSchema#string

Giovanna Chiorino

http://www.w3.org/2001/XMLSchema#string

Giuliana Cavalloni

http://www.w3.org/2001/XMLSchema#string

Luciano Mosso

http://www.w3.org/2001/XMLSchema#string

Massimo Aglietta

http://www.w3.org/2001/XMLSchema#string

Maurizia Mello-Grand

http://www.w3.org/2001/XMLSchema#string

Raffaella Segir

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression of forkhead transcription factors in the normal and diseased human prostate

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer

Cancer statistics, 2004

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.

Dysregulated expression of growth factors and their receptors in the development of prostate cancer.

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

P2888

1471-2407-11-31

P304

31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-31

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49784512

http://www.w3.org/2001/XMLSchema#string

P6179

1053491347

http://www.w3.org/2001/XMLSchema#string

P698

21266046

http://www.w3.org/2001/XMLSchema#string

P932

3040720

http://www.w3.org/2001/XMLSchema#string